Skip to main content
Clinical Trials/NCT03194347
NCT03194347CompletedNot Applicable

Clinical Value of Molecular Genetic Analyzes in Gynecological Malignomas

University Hospital Tuebingen1 site in 1 country300 target enrollmentStarted: May 29, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
300
Locations
1
Primary Endpoint
Influence of molecular genetic findings to the therapy decision

Study Overview

Brief Summary

The aim of the planned research project is to find out the clinical significance of molecular genetic analyzes in gynecological malignomas. In particular, it will be investigated how the knowledge of a molecular-genetic finding affects the therapeutic decision of the physician. Furthermore, genetic changes in the tumor tissue will be compared with the changes in CTCs, DTCs and cfDNA.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with a solid tumor disease
  • The presence of a molecular genetic diagnosis of the tumor tissue from practice for human genetics
  • Age > 18 years
  • informed consent

Exclusion Criteria

  • life expectancy <12 months or worse general condition (Karnofsky <70)

Outcomes

Primary Outcomes

Influence of molecular genetic findings to the therapy decision

Time Frame: 3years

It will be analyzed if the physicians selection of a therapy is influenced by a present molecular genetic finding. Therapy recommondation based on molecular genetic analysis will be compared with the acutal therapy decision.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials